Under construction – not a live service
Sign in
Taking people in SingaporeNo phase

Testing Drug Responses in Patient Tumour Models for Sarcoma and Melanoma

Grows models from tumour samples to test drug sensitivity in adults with sarcoma or melanoma.

Plain-language title generated from the registry record
Registry title: Using QPOP to Predict Treatment for Sarcomas and Melanomas

Key facts

Where
Singapore, SingaporeSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 99 years old?

Source: NCT04986748, who can take part

Where in Singapore

  • National Cancer Centre SingaporeSingapore, SingaporeTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
National Cancer Centre, Singapore
Trial code
NCT04986748
Record updated
1 July 2025
Original description
This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.Read full original descriptionShow less

Q-SAM (Using QPOP to Predict Treatment for Sarcomas and Melanomas)

This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.

Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.

Inclusion: Diagnosis of sarcoma or melanoma; At least 1 tumour lesion amenable to fresh biopsy or resection; Signed informed consent from patient or legal representative; Able to comply with study-related procedures.

Exclusion: There are no specific exclusion criteria if patients meet the inclusion criteria.

ClinicalTrials.gov NCT04986748